来自官方财务报表的收入、利润与现金流历史。
安进公司 (Amgen Inc.) 在全球范围内发现、开发、制造和提供人类治疗药物。该公司的主要产品包括用于治疗类风湿性关节炎、斑块状银屑病和银屑病关节炎的Enbrel； Otezla 用于治疗患有斑块型银屑病、银屑病关节炎和与白塞氏病相关的口腔溃疡的成年患者； Prolia 治疗绝经后妇女骨质疏松症； XGEVA 用于预防骨骼相关事件； Repatha，可降低心肌梗塞、中风和冠状动脉血运重建的风险； Nplate用于治疗免疫性血小板减少症患者； KYPROLIS 用于治疗复发或难治性多发性骨髓瘤患者； Aranesp 用于治疗红细胞数量低于正常水平和贫血； EVENITY 用于治疗女性绝经后骨质疏松症； Vectibix 用于治疗野生型 RAS 转移性结直肠癌患者； BLINCYTO用于治疗急性淋巴细胞白血病患者； TEPEZZA 治疗甲状腺眼病；和 KRYSTEXXA 用于治疗慢性难治性痛风。
机器翻译
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $38.1B | $36.7B | $33.4B | $28.2B | $26.3B | $26.0B | $25.4B | $23.4B | $23.7B | $22.8B | $23.0B | $21.7B | $20.1B | $18.7B | $17.3B | $15.6B | $15.1B | $14.6B | $15.0B | $14.8B | $14.3B |
| 毛利 | $27.7B | $26.0B | $20.6B | $19.7B | $19.9B | $19.5B | $19.3B | $19.0B | $19.6B | $18.8B | $18.8B | $17.4B | $15.6B | $15.3B | $14.3B | $13.2B | $12.8B | $12.6B | $12.7B | $12.2B | $12.2B |
| 毛利率% | 72.7% | 70.8% | 61.5% | 70.0% | 75.7% | 75.2% | 75.8% | 81.3% | 82.7% | 82.2% | 81.9% | 80.5% | 78.0% | 82.1% | 83.1% | 84.4% | 85.2% | 85.7% | 84.7% | 82.8% | 85.3% |
| 营业利润（EBIT） | $12.6B | $10.7B | $7.3B | $7.9B | $9.6B | $7.6B | $9.1B | $9.7B | $10.3B | $10.0B | $9.8B | $8.5B | $6.2B | $5.9B | $5.6B | $4.3B | $5.5B | $5.5B | $5.2B | $4.0B | $3.8B |
| 营业利润率% | 33.2% | 29.1% | 21.7% | 28.0% | 36.3% | 29.4% | 35.9% | 41.4% | 43.2% | 43.6% | 42.6% | 39.1% | 30.9% | 31.4% | 32.3% | 27.7% | 36.8% | 37.6% | 34.8% | 26.9% | 26.9% |
| 净利 | $8.7B | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B | $7.3B | $7.8B | $8.4B | $2.0B | $7.7B | $6.9B | $5.2B | $5.1B | $4.3B | $3.7B | $4.6B | $4.6B | $4.2B | $3.2B | $3.0B |
| 净利润率 % | 22.9% | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.4% | 8.7% | 33.6% | 32.0% | 25.7% | 27.2% | 25.2% | 23.6% | 30.7% | 31.4% | 28.0% | 21.4% | 20.7% |
| EBITDA | $16.5B | $16.9B | $13.4B | $7.9B | $12.2B | $11.3B | $13.0B | $12.6B | $12.9B | $12.9B | $12.5B | $11.2B | $8.7B | $7.6B | $7.2B | $5.8B | $6.9B | $6.8B | $6.6B | $6.0B | $6.0B |
| 每股收益（EPS） | $16.10 | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 | $12.31 | $12.88 | $12.62 | $2.69 | $10.24 | $9.06 | $6.70 | $6.64 | $5.52 | $4.04 | $4.79 | $4.51 | $3.90 | $2.82 | $2.48 |
| 已发行股数 (M) | 544M | 542M | 541M | 538M | 541M | 573M | 590M | 609M | 665M | 735M | 754M | 766M | 770M | 765M | 787M | 912M | 965M | 1,021M | 1,075M | 1,123M | 1,190M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 AMGN 交互式查看器。 /companies/us/AMGN
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms